Related Experiment Videos
[Tumor cell death as reflected by the SCC-antigen level?]
B P Clasen1, P Péré, R Senekowitsch
1Univ.-Hals-Nasen-Ohrenklinik und Poliklinik rechts der Isar der Technischen Universität München.
Laryngo- Rhino- Otologie
|May 1, 1991
Summary
Serum levels of squamous cell carcinoma (SCC) antigen in advanced head and neck cancers correlate with therapy response. Pre-treatment levels above 2 ng/ml suggest tumor association and impact treatment outcomes.
Area of Science:
- Oncology
- Biochemistry
Context:
- Advanced head and neck cancers present complex therapeutic challenges.
- Squamous cell carcinoma (SCC) associated antigen is a potential biomarker.
- Understanding SCC antigen's role in therapy response is crucial for patient management.
Purpose:
- To investigate the relationship between serum SCC antigen levels and the course of therapy in advanced head and neck cancers.
- To determine if pre-treatment SCC antigen levels can predict tumor association and influence treatment outcomes.
Summary:
- Serum SCC antigen levels were analyzed in 91 advanced head and neck cancer patients.
- Levels below 2 ng/ml showed no relation to tumor growth, while levels above 2 ng/ml were tumor-associated.
- Distinct responses to radiochemotherapy were observed between high and low SCC antigen groups, suggesting different biological activities and potential links to clinical malignancy.
Impact:
- Findings suggest serum SCC antigen levels may serve as a prognostic indicator in head and neck cancer.
- Differentiated biological activity associated with SCC antigen levels could inform personalized treatment strategies.
- Further research is warranted to explore the link between SCC antigen levels, tumor biology, and clinical outcomes.